medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2014, Número 1

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2014; 12 (1)


Dapsona: su uso en dermatología

Clavellina MM, Moreno CG

Idioma: Español
Referencias bibliográficas: 39
Paginas: 47-51
Archivo PDF: 216.76 Kb.


RESUMEN

Aunque no se ha esclarecido el mecanismo de acción de la dapsona y sus metabolitos, se ha demostrado su eficacia en dos grupos de patologías: infecciones y enfermedades inflamatorias crónicas.
En dermatología, dapsona es el medicamento de primera elección para el tratamiento de ciertos trastornos inflamatorios y diversas dermatosis neutrófilicas, eosinofílicas o autoinmunes


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Fromm E, Wittmann J. “Derivate des p-nitrothiophenols”. Berichte Deutsch ChemGes 1908; 41: 2264-2273.

  2. Doull JA. “Sulfone therapy of leprosy. Background, early history and present status”. Int J Lepr 1963; 31: 143-160.

  3. Boyer H, Nitti F, Tréfouel J. “Note preliminaire sur l’action de la paradiacetyl- aminodiphenyl-sulfone (1399F) dans la blennorragie”. Bull Soc Fr Dermatol Syphiligr 1937; 44:1889.

  4. Palazzoli M, Bovill D. “Action de la di (paracetyhiminophenyl) sulfone (1399F) dans les uretrites gonococciques aigues et chroniques”. Dermatol Syphiligr 1900-1910 (1937): 44.

  5. Buttle GAH, Stephenson D, Smith S, et al. “The treatment of streptococcal infections in mice with diaminodiphenylsulfone”. Lancet 1937; 1: 1331-1334.

  6. Fourneau E, Tréfouel J, Nitti F, et al. “Action anti-streptococcique derivés sulfurés organiques”. C R AcadSci 1937; 204: 1763-1766.

  7. Faget GH, Pogge RC, Johansen FA, et al. “The promin treatment of leprosy”. Public Health Rep 1943; 58: 1729-1741.

  8. Esteves J, Brandao FN. “Acerca da accao das sulfamidas e das sulfonas na doenca de Duhring. Trab Soc Portuguesa”. Dermatol Venereol 1950; 8: 209-217.

  9. Sneddon IB, Wilkinson DS. “Subcorneal pustular dermatosis”. Br J Dermatol 1956; 68: 385-394.

  10. Wozel G, editor. Dapson—Pharmakologie, Wirkmechanismus und klinischer Einsatz. Stuttgart (Alemania), Georg Thieme Verlag, 1996.

  11. Ahmad RA, Rogers HJ. “Pharmacokinetics and protein-binding of dapsone and pyrimethamine”. Br J ClinPharmacol 1980; 10: 519-524.

  12. Mc Evoy GK, editor. “AHFS drug information”. Bethesda (MD): American Society of Health-System Pharmacists; 2009; 605–609.

  13. Zuidema J. “Clinical pharmacokinetics of dapsone”. Clin Pharmacokinet 1986; 11: 299-315.

  14. Branski D, Kerem E, Gross-Kieselstein E, et al. “Bloody diarrhea—a possible complication of sulfasalazine transferred through human breast milk”. J Pediatr Gastroenterol Nutr 1986; 5: 316-317.

  15. Sanders SW, Zone JJ, Foltz RL, et al. “Hemolyticanemia induced by dapsone transmitted through breast milk”. Ann Intern Med 1982; 96: 465-466.

  16. Zhu YI, Stiller MJ. “Dapsone and sulfones in dermatology: overview and update”. J Am AcadDermatol 2001; 45: 420-434.

  17. Wozel G, Barth J. “Current aspects of modes of action of dapsone”. Int J Dermatol 1988; 27: 547-552.

  18. Niwa Y, Sakane T, Miyachi Y. “Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediate—in comparison with that of colchicine and various scavengers”. BiochemPharmacol 1984; 33: 2344-2360.

  19. Niwa Y, Sakane T, Shingu M, et al. “Neutrophil-generated active oxygens in linear IgA bullous dermatosis”. Arch Dermatol 1985; 121: 73-78.

  20. Miyachi Y, Niwa Y. “Effects of potassium iodide, colchicine and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates”. Br J Dermatol 1982; 107: 209-214.

  21. Hamada K, Hiyoshi T, Kobayashi S, et al. “Anticonvulsive effect of dapsone (4,40-diaminodiphenylsulfone) on amygdale-kindled seizures in rats and cats”. Epilepsy Res 1991; 10: 93-102.

  22. Ishida S, Hamada K, Yagi K. “Comparing the anticonvulsive effects of dapsone on amygdale-kindled seizures and hippocampal-kindled seizures in rats”. Acta Neurol Scand 1992; 85: 132-135.

  23. Altagracia M, Monroy Noyola A, Osorio Rico L, et al. “Dapsone attenuates kainic acid-induced seizures in rats”. Neurosci Lett 1994; 176: 52-54.

  24. Díaz Ruiz A, Zavala C, et al. “Antioxidant, Antiinflammatory and Antiapoptotic Effects of Dapsone in a Model of Brain Ischemia/Reperfusion in Rats”. Journal of Neuroscience Research 2008; 86: 3410-3419.

  25. Schumacher K. Humane “In-vivo-Untersuchungen zur antientzündlichen Wirksamkeit von Diaminodiphenylsulfon (Dapson)”. Departamento de Dermatología, Hospital Universitario Carl Gustav Carus, Dresden, Alemania 1996; tesis.

  26. Pfeiffer CH, Wozel G. “Comments to ‘Dapsone and sulfones in dermatology: overview and update’”. J Am AcadDermatol 2003; 48: 308-309.

  27. Gottfried W. “Innovative Use of Dapsone”. DermatolClin 2010; 28: 599-610.

  28. Draelos ZD, Carter E, Maloney JM, et al. “Two randomized studies demonstrate the efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris”. J Am Acad Dermatol 2007; 56: 439 e1-10.

  29. Nestle FO, Kaplan DH, Barker J. “Mechanisms of disease: psoriasis”. N Engl J Med 2009; 361: 496-509.

  30. Bundino S, Zina AM, Ubertalli S. “Infantile acropustulosis”. Dermatologica 1982; 165: 615-619.

  31. Frayling IM, Addison GM, Chattergee K, et al. “Methaemoglobinaemia in children treated with prilocaine-lignocaine cream”. Br Med J 1990;301:153-154.

  32. Grunwald MH, Amichai B. “Dapsone – the treatment of infectious and inflammatory diseases in dermatology”. Int J Antimicrob Agents 1996; 7: 187-192.

  33. Coleman MD. “Dapsone toxicity: some current perspectives”. Gen Pharmacol 1995; 26: 1461-1467.

  34. Rhodes LE, Tingle MD, Park BK, et al. “Cimetidine improves the therapeutic/ toxic ratio of dapsone in patients on chronic dapsone therapy”. Br J Dermatol 1995; 132: 257-262.

  35. Stöckel S, Meurer M, Wozel G. “Dapsone-induced photodermatitis in a patient with linear IgA dermatosis”. Eur J Dermatol 2001; 11: 50-53.

  36. Homeida M, Babikr A, Daneshmend TK. “Dapsone-induced optic atrophy and motor neuropathy”. Br Med J 1980; 281: 1180.

  37. Kenner DJ, Holt K, Agnello R, et al. “Permanent retinal damage following massive dapsone overdose”. Br J Ophthalmol 1980; 64: 741-744.

  38. Belmont A. “Dapsone-induced nephrotic syndrom”. JAMA 1978; 200: 262-263.

  39. Hoffbrand BI. “Dapsone and renal papillary necrosis”. Br Med J 1978; 1: 78.




2020     |     www.medigraphic.com